Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Ticlopidine |
EINECS | 259-498-5 |
CAS No. | 55142-85-3 | Density | 1.273±0.06 g/cm3(Predicted) |
PSA | 31.48000 | LogP | 3.89770 |
Solubility | N/A | Melting Point |
210-212 °C |
Formula | C14H14 Cl N S | Boiling Point | 117-120 °C(Press: 0.5 Torr) |
Molecular Weight | 263.791 | Flash Point | N/A |
Transport Information | N/A | Appearance | N/A |
Safety | Risk Codes | R34 | |
Molecular Structure | Hazard Symbols | C,Xi | |
Synonyms |
PCR 5332;Ticlid; Ticlopidine; Tiklyd |
Article Data | 16 |
Molecular structure of Ticlopidine (CAS NO.55142-85-3) is:
Product Name: Ticlopidine
CAS Registry Number: 55142-85-3
IUPAC Name: 5-[(2-Chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
Molecular Weight: 263.78566 [g/mol]
Molecular Formula: C14H14ClNS
XLogP3-AA: 3.6
H-Bond Donor: 0
H-Bond Acceptor: 1
EINECS: 259-498-5
Index of Refraction: 1.638
Molar Refractivity: 74.43 cm3
Molar Volume: 207 cm3
Surface Tension: 51.5 dyne/cm
Density: 1.273 g/cm3
Flash Point: 175.9 °C
Enthalpy of Vaporization: 61.38 kJ/mol
Boiling Point: 367.3 °C at 760 mmHg
Vapour Pressure: 1.38E-05 mmHg at 25 °C
Classification Code: Cardiovascular Agents ;Drug / Therapeutic Agent ;Fibrin Modulating Agents ;Fibrinolytic agents ;Hematologic Agents ;Human Data ;Platelet aggregation inhibitors
Canonical SMILES: C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
InChI: InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
InChIKey: PHWBOXQYWZNQIN-UHFFFAOYSA-N
Ticlopidine (CAS NO.55142-85-3) can be used in these actions:
1、Inihibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents platelet expression of glycoprotein IIb/IIIa which prevents platelet binding to fibrinogen.
2、Prolongs bleeding time.
3、Decreased incidence of stroke in high-risk patients.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
man | LDLo | oral | 336mg/kg/47D- (336mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BLOOD: AGRANULOCYTOSIS BLOOD: THROMBOCYTOPENIA | Annals of Pharmacotherpy. Vol. 28, Pg. 1236, 1994. |
man | TDLo | oral | 350mg/kg/7W-I (350mg/kg) | BLOOD: AGRANULOCYTOSIS | Postgraduate Medical Journal. Vol. 74, Pg. 126, 1998. |
man | TDLo | oral | 429mg/kg/6OD- (429mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Lancet. Vol. 1, Pg. 407, 1984. |
monkey | LD50 | intraperitoneal | 500mg/kg (500mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): HAIR: OTHER LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING | New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983. |
monkey | LD50 | oral | > 6gm/kg (6000mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING SKIN AND APPENDAGES (SKIN): HAIR: OTHER | New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983. |
mouse | LD50 | intraperitoneal | 1250mg/kg (1250mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): HAIR: OTHER LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING | New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983. |
mouse | LD50 | intravenous | 88mg/kg (88mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING SKIN AND APPENDAGES (SKIN): HAIR: OTHER | New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983. |
mouse | LD50 | oral | 600mg/kg (600mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING SKIN AND APPENDAGES (SKIN): HAIR: OTHER | New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983. |
rat | LD50 | intraperitoneal | > 5gm/kg (5000mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): HAIR: OTHER LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING | New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983. |
rat | LD50 | intravenous | 70mg/kg (70mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): HAIR: OTHER LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING | New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983. |
rat | LD50 | oral | 1780mg/kg (1780mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING SKIN AND APPENDAGES (SKIN): HAIR: OTHER | New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983. |
women | TDLo | oral | 100mg/kg/10D- (100mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED BLOOD: EOSINOPHILIA | American Journal of Kidney Diseases. Vol. 25, Pg. 934, 1995. |
women | TDLo | oral | 350mg/kg/5W-I (350mg/kg) | LIVER: LIVER FUNCTION TESTS IMPAIRED | Annals of Pharmacotherpy. Vol. 33, Pg. 939, 1999. |
women | TDLo | oral | 600mg/kg/60D- (600mg/kg) | BLOOD: APLASTIC ANEMIA BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE | Israel Journal of Medical Sciences. Vol. 31, Pg. 444, 1995. |
Ticlopidine , its cas register number is 55142-85-3. It also can be called Ticlopidine [INN:BAN] ; 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine ; Ticlopidina ; Ticlopidinum ; Thieno(3,2-c)pyridine, 4,5,6,7-tetrahydro-5-((2-chlorophenyl)methyl)- ; Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro- .It is an antiplatelet drug in the thienopyridine family. Also it is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis.